Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
作者:Xiaozhang Zheng、Paul Bauer、Timm Baumeister、Alexandre J. Buckmelter、Maureen Caligiuri、Karl H. Clodfelter、Bingsong Han、Yen-Ching Ho、Nikolai Kley、Jian Lin、Dominic J. Reynolds、Geeta Sharma、Chase C. Smith、Zhongguo Wang、Peter S. Dragovich、Angela Oh、Weiru Wang、Mark Zak、Janet Gunzner-Toste、Guiling Zhao、Po-wai Yuen、Kenneth W. Bair
DOI:10.1021/jm400186h
日期:2013.6.27
group was the preferred substituent at one inhibitor terminus and also identified a urea moiety as the optimal linker to the remainder of the inhibitor structure. Further SAR optimization of the other inhibitor terminus ultimately yielded compound 50 as a urea-containing Nampt inhibitor which exhibited excellent biochemical and cellular potency (enzyme IC50 = 0.007 μM; A2780 IC50 = 0.032 μM). Compound
烟酰胺磷酸核糖基转移酶(Nampt)是一种有希望的抗癌靶标。虚拟筛选确定了一种硫脲类似物化合物5为新型强效Nampt抑制剂。在5的共晶结构的指导下,SAR探索表明相应的脲化合物7表现出相似的效价,并具有改善的溶解度特征。这些研究还表明3-吡啶基是在一个抑制剂末端的优选取代基,并且还确定了脲部分是抑制剂结构其余部分的最佳连接基。另一个抑制剂末端的进一步SAR优化最终产生了化合物50作为具有尿素的Nampt抑制剂,它具有出色的生化和细胞效价(酶IC 50 = 0.007μM; A2780 IC 50 = 0.032μM)。当在A2780卵巢肿瘤异种移植模型中口服给药时,化合物50还显示出优异的体内抗肿瘤功效(在第17天观察到TGI为97%)。